Kvika Asset Management

PLAIO is an AI-powered planning platform specifically designed for the pharmaceutical industry, aimed at transforming supply chain and operational management. The platform replaces traditional spreadsheet-based planning with advanced AI, machine learning, and real-time data analytics, optimizing demand, manufacturing, and purchasing processes. It integrates seamlessly with existing ERP systems, enhancing data-driven decision-making and improving forecast accuracy while streamlining planning workflows. Tailored for small to medium-sized pharmaceutical manufacturers and virtual pharma companies, PLAIO helps clients mitigate risks, reduce costs, and increase efficiency in a highly regulated and competitive landscape. The platform features capabilities such as visual and capacity planning, advanced constraint calculations, what-if analysis, AI-based automation, and scalability, enabling agile manufacturing operations and precise product output.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on treating inflammatory disorders by enhancing epithelial barrier integrity, a crucial factor in various diseases. Epithelial cells comprise significant components of human skin, lung tissue, the intestinal tract, and genitalia, with compromised barrier integrity linked to persistent inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates aimed at addressing the substantial global burden of chronic respiratory diseases and other unmet medical needs. Its lead candidate, EP395, is designed to be the first oral, disease-modifying, non-antibiotic macrolide that strengthens barriers and reduces inflammation, targeting conditions such as chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases. Through its innovative approach, EpiEndo seeks to provide effective treatments that improve patient outcomes.